Malignant tumor of extrahepatic bile duct

Summary

Malignant tumor of extrahepatic bile duct (MONDO:0021321) is a cancer and 66 clinical trials. Top therapeutic interventions include lapatinib, cisplatin, and gemcitabine. A subtype of bile duct cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 66

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant tumor of extrahepatic bile duct
Mondo ID	MONDO:0021321
ICD-10-CM	C24.0
NCIT	C7483
SNOMED CT	363416002
UMLS	C0153453
MedGen	56304
GARD	0025312
Anatomy (UBERON)	UBERON:0003703
Is cancer (heuristic)	yes

Also known as: cancer of extrahepatic bile duct · extrahepatic bile duct cancer · malignant extrahepatic bile duct neoplasm · malignant extrahepatic bile duct tumor · malignant extrahepatic bile duct tumour · malignant neoplasm of extrahepatic bile duct · malignant neoplasm of the extrahepatic bile duct · malignant tumor of the extrahepatic bile duct · malignant tumour of the extrahepatic bile duct

Disease family

This is a subtype of bile duct cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › malignant tumor of extrahepatic bile duct

Related subtypes (3): intrahepatic bile duct cancer, bile duct sarcoma, bile duct carcinoma

Subtypes (3): ampulla of vater cancer, extrahepatic bile duct carcinoma, extrahepatic bile duct sarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 66.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	30
PHASE1	14
Not specified	9
PHASE3	8
PHASE1/PHASE2	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00253617	PHASE3	WITHDRAWN	Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
NCT00262769	PHASE3	COMPLETED	Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
NCT00304135	PHASE2/PHASE3	COMPLETED	Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
NCT00363584	PHASE3	COMPLETED	Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
NCT00387348	PHASE3	TERMINATED	Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
NCT00513539	PHASE3	COMPLETED	Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
NCT00658593	PHASE3	TERMINATED	Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
NCT01313377	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
NCT02349412	PHASE3	COMPLETED	Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
NCT00003296	PHASE2	UNKNOWN	Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
NCT00003557	PHASE2	COMPLETED	Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
NCT00003923	PHASE2	COMPLETED	Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
NCT00004895	PHASE2	COMPLETED	Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
NCT00004910	PHASE1/PHASE2	COMPLETED	Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
NCT00005938	PHASE2	COMPLETED	DX-8951f in Treating Patients With Biliary Cancer
NCT00005997	PHASE2	TERMINATED	Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
NCT00009893	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
NCT00010088	PHASE2	UNKNOWN	Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
NCT00012246	PHASE2	TERMINATED	Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
NCT00019474	PHASE2	COMPLETED	Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
NCT00021047	PHASE1/PHASE2	COMPLETED	Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
NCT00023946	PHASE2	TERMINATED	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00030511	PHASE2	TERMINATED	Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
NCT00033462	PHASE2	COMPLETED	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
NCT00033540	PHASE2	COMPLETED	S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00059865	PHASE1/PHASE2	COMPLETED	Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
NCT00073905	PHASE2	COMPLETED	Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
NCT00084942	PHASE2	COMPLETED	Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
NCT00085410	PHASE2	TERMINATED	Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
NCT00101036	PHASE2	COMPLETED	Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
NCT00107536	PHASE2	COMPLETED	Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
NCT00238212	PHASE2	COMPLETED	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00356889	PHASE2	COMPLETED	Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
NCT00478140	PHASE2	TERMINATED	Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
NCT00553332	PHASE2	COMPLETED	Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
NCT00789958	PHASE2	COMPLETED	S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
NCT00832637	PHASE2	TERMINATED	Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
NCT00903396	PHASE2	TERMINATED	Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
NCT00919061	PHASE2	COMPLETED	Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
NCT01229111	PHASE2	TERMINATED	Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	6
CISPLATIN	4	5
GEMCITABINE	4	4
PORFIMER SODIUM	4	3
EPIRUBICIN HYDROCHLORIDE	4	2
ERLOTINIB	4	2
OXALIPLATIN	4	2
SELUMETINIB	4	2
APREPITANT	4	1
CAPECITABINE	4	1
CITALOPRAM	4	1
ESCITALOPRAM	4	1
HYDROXYUREA	4	1
IXABEPILONE	4	1
OCTREOTIDE ACETATE	4	1
PALONOSETRON HYDROCHLORIDE	4	1
SARGRAMOSTIM	4	1
SORAFENIB	4	1
EXATECAN	3	2
BECATECARIN	3	1
CEDIRANIB MALEATE	3	1
CPI 613	3	1
INCOMPLETE FREUND’S ADJUVANT	3	1
MOTEXAFIN GADOLINIUM	3	1
DOLASTATIN-10	2	1
EDODEKIN ALFA	2	1
UCN-01	2	1
CHEMBL4463209	0	2
CHEMBL1236539	0	1